



Notification of forthcoming release of escrowed securities

Sydney, Australia, Friday, 9 April 2021: Next Science Limited (ASX:NXS) (**Next Science / Company**) advises, in accordance with Listing Rule 3.10A, that 72,847,807 fully paid ordinary shares and 5,850,000 options (**Escrowed Securities**) will be released from escrow on 18 April 2021.

The Escrowed Securities have been subject to a mandatory ASX imposed escrow restriction for 24 months since the date of official quotation of Next Science ordinary fully paid shares on 18 April 2019.

Approved and authorised by the Managing Director.

Further information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: www.nextscience.com.